Health Care & Life Sciences » Pharmaceuticals | Titan Pharmaceuticals Inc.

Titan Pharmaceuticals Inc. | Cash Flow

Fiscal year is January-December. All values USD Thousands.
2013
2014
2015
2016
2017
2018
Net Income before Extraordinaries
9,711.00
2,403.00
11,279.00
5,135.00
14,307.00
9,023
Depreciation, Depletion & Amortization
107.00
353.00
358.00
377.00
417.00
380
Other Funds
11,881.00
540.00
5,538.00
214.00
1,209.00
620
Funds from Operations
2,063.00
2,590.00
5,383.00
5,726.00
12,681.00
8,023
Changes in Working Capital
7,736.00
3,275.00
2,083.00
567.00
357.00
408
Net Operating Cash Flow
9,799.00
5,865.00
7,466.00
6,293.00
13,038.00
8,431
Capital Expenditures
318.00
18.00
133.00
171.00
175.00
Net Investing Cash Flow
318.00
18.00
133.00
171.00
175.00
Issuance/Reduction of Debt, Net
2,500.00
-
-
-
6,729.00
Net Financing Cash Flow
3,813.00
9,555.00
14.00
27.00
6,729.00
Net Change in Cash
6,304.00
3,672.00
7,613.00
6,149.00
6,484.00
Free Cash Flow
10,117.00
5,883.00
7,599.00
6,122.00
13,213.00
Change in Capital Stock
6,313.00
9,555.00
14.00
27.00
-

About Titan Pharmaceuticals

View Profile
Address
400 Oyster Point Boulevard
South San Francisco California 94080
United States
Employees -
Website http://www.titanpharm.com
Updated 07/08/2019
Titan Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in developing proprietary therapeutics primarily for the treatment of medical disorders. Its products include Probuphine, provides non fluctuating blood levels of buprenorphine; Ropinirole implant, which provides dopaminergic stimulation; and T3 implant, which is used in hypothyroidism treatment. Its products are subdermal implants, which utilizes ProNeura drug delivery platform.

StatInvestor

Privacy Policy
Feedback

© 2024 StatInvestor All Rights Reserved.